MediWound Ltd., a fully-integrated biopharmaceutical, announced that the US Food and Drug Administration (FDA) has approved NexoBrid (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.
Found this useful? Share it with your team.
